13 Sep 2016
The most accurate de novo antibody sequencing service available, guaranteed
Digital Proteomics and LakePharma Inc. announce the release of the next generation of de novo antibody sequencing service. The new service combines Digital Proteomics’ patented algorithm, Valens, with LakePharma’s expertise in antibody engineering and expression. The final deliverable is an antibody sequence with experimentally validated antigen binding. Without any prior knowledge of the sequence (no DNA required), the new service determines the primary sequences of a monoclonal antibody’s heavy and light chains, with guaranteed expression and antigen-binding. Contact us today for more information!
LakePharma is a leading contract research organization (CRO) specializing in antibody and protein engineering, cell line development, protein expression, and characterization. With facilities located in the heart of the San Francisco Bay Area and near the Boston/Cambridge biotech hub, LakePharma has developed numerous in-house technology platforms to provide cost-effective and high-quality services to its customers. Services can be fully integrated, creating a one-stop-shop solution for all of a customer’s molecular biology, cell line, and protein needs.
For more information: